Clinical Trials for Relapsed Cancer

1. A Safety and Pharmacokinetic Study of Single Agent REGN2810 in Pediatric Patients with Relapsed or Refractory Solid or Central Nervous System (CNS) Tumors and a Safety and Efficacy Trial of REGN2810 in Combination with Radiotherapy in Pediatric Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Newly Diagnosed High-Grade Glioma, or Recurrent High-Grade Glioma
   Principal Investigator Susan Chi, MD
2. A Phase I/II and Target Validation Study of TAK-580 (MLN2480) for Children with Low-Grade Gliomas and Other RAS/RAF/MEK/ERK Pathway Activated Tumors
   Principal Investigator Karen Wright, MD
3. Phase II open-label global study to evaluate the effect of dabrafenib in combination with trametinib in children and adolescent patients with BRAF V600 mutation positive relapsed or refractory High-Grade Glioma (HGG)
   Principal Investigator Karen Wright, MD
4. A Phase I Study of Ad-RTS-hIL-12, an Inducible Adenoviral Vector Engineered to Express hIL-12 in the Presence of the Activator Ligand Veledimex in Pediatric Brain Tumor Subjects
   Principal Investigator Susan Chi, MD
5. PNOC 005: A Phase 1 Study of Modified Measles Virus (MV-NIS) for the Treatment of Children and Young Adults with Recurrent Medulloblastoma or Recurrent Atypical Teratoid Rhabdoid Tumors (ATRT)
   Principal Investigator Susan Chi, MD
6. A Phase 1/2 Study of VX15/2503 (IND# 136181) in Children, Adolescents, or Young Adults with Recurrent or Relapsed Solid Tumors
   Principal Investigator Steven DuBois, MD
7. Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer
   Principal Investigator Steven DuBois, MD
8. A Phase 1 Study of Pevonedistat (MLN4924, IND# 136078), A NEDD8 Activating Enzyme (NAE) Inhibitor, In Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors
   Principal Investigator Steven DuBois, MD
9. A Phase 1 Study of ABI-009 (Nab-Rapamycin) (IND# 133537) In Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors As A Single Agent and in Combination with Temozolomide and Irinotecan
   Principal Investigator Steven DuBois, MD
10. Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
    Principal Investigator Suzanne Shusterman, MD
11. A Phase I Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors
    Principal Investigator Steven DuBois, MD
12. A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
    Principal Investigator Steven DuBois, MD
13. A Phase 1/2 Study of Lenvatinib in Combination with Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
    Principal Investigator Steven DuBois, MD
14. A Phase 1/2 Study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects with Previously Treated NTRK Fusion Cancers
    Principal Investigator Steven DuBois, MD
15. A Phase 1/2 Study of AZD1775 (MK-1775) In Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors
    Principal Investigator Steven DuBois, MD
16. Phase 1 Trial of CUDC-907 in Children and Young Adults with Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
    Principal Investigator Steven DuBois, MD
17. A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma
    Principal Investigator Steven DuBois, MD
18. PNOC 002: Safety, Phase 0, and Pilot Efficacy Study of Vemurafenib, an oral inhibitor of BRAFV600E, in Children and Young Adults with Recurrent/Refractory BRAFV600E or BRAF Ins T mutant Brain Tumors
    Principal Investigator Susan Chi, MD
19. A Phase 1 Study of Selinexor (KPT-330), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
    Principal Investigator Suzanne Shusterman, MD
20. A Phase I/II, Multicenter, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients with Previously Treated Solid Tumors
    Principal Investigator Steven DuBois, MD
21. A Phase I Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects with Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
    Principal Investigator Susan Chi, MD
22. A Phase II Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapse or Refractory Synovial Sarcoma
    Principal Investigator Gregory Cote, MD
23. Phase I-II Study of MEK162 for Children Low-Grade Gliomas and Other Ras/Raf/ERK Pathway Activated Tumors
    Principal Investigator Karen Wright, MD
24. Phase I Open Label, Dose Escalation, Monotherapy Trial of Afatinib to Determine the MTD, Safety, PK and Efficacy of Afatinib in Children Aged 2 Years to <18 Years with Recurrent/Refractory Neuroectodermal Tumours, Rhabdomyosarcoma and Tumours with ErbB Pathway Deregulation
    Principal Investigator Karen Wright, MD
25. Open-label, Phase 2 Study of Bevacizumab in Children and Adults with Neurofibromatosis 2 and Progressive Vestibular Schwannomas That Are Poor Candidates for Standard Treatment with Surgery or Radiation
    Principal Investigator Nicole Ullrich, MD
26. PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-Grade Glioma in Children
    Principal Investigator Susan Chi, MD
27. A Phase II Study of metronomic and targeted anti-angiogenesis therapy for children with recurrent/progressive medulloblastoma
    Principal Investigator Susan Chi, MD

Contact us
Not sure which clinical trials might be right for your child? Email our clinical trials team at clinicaltrials@danafarberbostonchildrens.org.

1. Phase I trial of ribociclib in combination with everolimus and dexamethasone in children and young adults with relapsed acute lymphoblastic leukemia
   Principal Investigator Andrew Place, MD
2. Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer
   Principal Investigator: Steven DuBois, MD
3. T2012-002: A Pilot Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination with UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults with Relapse of Acute Lymphoblastic Leukemia
   Principal Investigator Andrew Place, MD
4. Phase I study of carfilzomib in combination with cyclophosphamide and etoposide for children with relapsed and refractory solid tumors and leukemias
   Principal Investigator Steven DuBois, MD
5. A Phase I Trial of Temsirolimus (CCI-779, Pfizer, Inc) in Combination with Etoposide and Cyclophosphamide in Children with Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma
   Principal Investigator Lewis Silverman, MD

Contact us
Not sure which clinical trials might be right for your child? Email our clinical trials team at clinicaltrials@danafarberbostonchildrens.org.

1. A Phase 1/2 Study of VX15/2503 (IND# 136181) in Children, Adolescents, or Young Adults with Recurrent or Relapsed Solid Tumors
   Principal Investigator Steven DuBois, MD
2. Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer
   Principal Investigator Steven DuBois, MD
3. A Non-Randomized, Open-Label, Multi-Center, Phase I/II Study of PI3K Inhibitor Copanlisib in Pediatric Patients with Relapsed/Refractory Solid Tumors or Lymphoma
   Principal Investigator Steven DuBois, MD
4. A Phase 1 Study of Pevonedistat (MLN4924, IND# 136078), A NEDD8 Activating Enzyme (NAE) Inhibitor, In Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors
   Principal Investigator Steven DuBois, MD
5. A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients with Relapsed or Refractory Malignancies
   Principal Investigator Andrew Place, MD
6. A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab
   Principal Investigator Steven DuBois, MD
7. A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
   Principal Investigator Steven DuBois, MD
8. Phase 1 Trial of CUDC-907 in Children and Young Adults with Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
   Principal Investigator Steven DuBois, MD
9. A Phase I/II Study of Pembrolizumab (MK-3475) in Children with Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma
   Principal Investigator Steven DuBois, MD
10. A Phase 1 Study of Selinexor (KPT-330), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
    Principal Investigator Suzanne Shusterman, MD
11. Phase I Study of Carfilzomib in Combination with Cyclophosphamide and Etoposide for Children with Relapsed and Refractory Solid Tumors and Leukemias
    Principal Investigator Steven DuBois, MD
12. An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor Trametinib in Children and Adolescents Subjects with Cancer or Plexiform Neurofibromas and Trametinib in Combination with Dabrafenib in Children and Adolescents with Cancers Harboring V600 Mutations
    Principal Investigator Karen Wright, MD
13. A Phase I Trial of Temsirolimus in Combination with Etoposide and Cyclophosphamide in Children with Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma
    Principal Investigator Lewis Silverman, MD
14. A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Safety and Efficacy of Tisagenlecleucel in Pediatric Patients with Relapsed or Refractory Mature B-Cell Non-Hodgkin Lymphoma (NHL) (BIANCA)
    Principal Investigator Kimberly J. Davies, MD

Contact us
Not sure which clinical trials might be right for your child? Email our clinical trials team at clinicaltrials@danafarberbostonchildrens.org.

1. NANT 2017-01: A Phase I Study Of 131I-MIBG With Dinutuximab For Relapsed/Refractory Neuroblastoma
   Principal Investigator Suzanne Shusterman, MD
2. NANT 2015-02: Phase 1 Study Of Lorlatinib (PF-06463922), An Oral Small Molecule Inhibitor Of ALK/ROS1, For Patients With ALK-Driven Relapsed Or Refractory Neuroblastoma
   Principal Investigator Suzanne Shusterman, MD
3. A Phase 1 Study of Pevonedistat (MLN4924, IND# 136078), A NEDD8 Activating Enzyme (NAE) Inhibitor, In Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors
   Principal Investigator Steven DuBois, MD
4. A Phase 1 Study of ABI-009 (Nab-Rapamycin) (IND# 133537) In Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors as a Single Agent and in Combination with Temozolomide and Irinotecan
   Principal Investigator Steven DuBois, MD
5. A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients with Relapsed or Refractory Malignancies
   Principal Investigator Andrew Place, MD
6. A Phase 1/2 Study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects with Previously Treated NTRK Fusion Cancers
   Principal Investigator Steven DuBois, MD
7. A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors
   Principal Investigator Steven DuBois, MD, MS
8. A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
   Principal Investigator Steven DuBois, MD, MS
9. A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab
   Principal Investigator Steven DuBois, MD
10. A Phase 1/2 Study of AZD1775 (MK-1775) In Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors
    Principal Investigator Steven DuBois, MD
11. Phase 1 Trial of CUDC-907 in Children and Young Adults with Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
    Principal Investigator Steven DuBois, MD
12. A Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX-101) in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors
    Principal Investigator Steven DuBois, MD
13. Phase I Study of Carfilzomib in Combination with Cyclophosphamide and Etoposide for Children with Relapsed and Refractory Solid Tumors and Leukemias
    Principal Investigator Steven DuBois, MD
14. A Phase I/II, Multicenter, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients with Previously Treated Solid Tumors
    Principal Investigator Steven DuBois, MD
15. A Phase 1 Study of Selinexor (KPT-330), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
    Principal Investigator Suzanne Shusterman, MD
16. Phase I Open Label, Dose Escalation, Monotherapy Trial of Afatinib to Determine the MTD, Safety, PK and Efficacy of Afatinib in Children Aged 2 Years to <18 Years with Recurrent/Refractory Neuroectodermal Tumours, Rhabdomyosarcoma and Tumours with ErbB Pathway Deregulation
    Principal Investigator Mark Kieran, MD

Contact us
Not sure which clinical trials might be right for your child? Email our clinical trials team at clinicaltrials@danafarberbostonchildrens.org.

1. A Phase 1/2 Study of VX15/2503 (IND# 136181) in Children, Adolescents, or Young Adults with Recurrent or Relapsed Solid Tumors
   Principal Investigator: Steven DuBois, MD
2. Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer
   Principal Investigator: Steven DuBois, MD
3. A Safety and Pharmacokinetic Study of Single Agent REGN2810 in Pediatric Patients with Relapsed or Refractory Solid or Central Nervous System (CNS) Tumors and a Safety and Efficacy Trial of REGN2810 in Combination with Radiotherapy in Pediatric Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Newly Diagnosed High-Grade Glioma, or Recurrent High-Grade Glioma
   Principal Investigator: Susan Chi, MD
4. A Phase 1 Study of Pevonedistat (MLN4924, IND# 136078), A NEDD8 Activating Enzyme (NAE) Inhibitor, In Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors
   Principal Investigator Steven DuBois, MD
5. A Phase 1 Study of ABI-009 (Nab-Rapamycin) (IND# 133537) In Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors As A Single Agent and in Combination with Temozolomide and Irinotecan
   Principal Investigator Steven DuBois, MD
6. Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
   Principal Investigator Suzanne Shusterman, MD
7. A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients with Relapsed or Refractory Malignancies
   Principal Investigator Andrew Place, MD
8. A Phase 1/2 Study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects with Previously Treated NTRK Fusion Cancers
   Principal Investigator Steven DuBois, MD
9. Phase 1 Study of Pazopanib in Combination with Irinotecan and Temozolomide (PAZIT) for Children and Young Adults with Relapsed or Refractory Sarcoma
   Principal Investigator Steven DuBois, MD
10. A Phase II Study of Pazopanib (GW786034, NSC# 737754 in Children, Adolescents and Young Adults with Refractory Solid Tumors
    Principal Investigator Suzanne Shusterman, MD
11. A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors
    Principal Investigator Steven DuBois, MD, MS
12. A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab
    Principal Investigator Steven DuBois, MD
13. A Phase 1/2 Study of AZD1775 (MK-1775) In Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors
    Principal Investigator Steven DuBois, MD
14. Phase 1 Trial of CUDC-907 in Children and Young Adults with Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
    Principal Investigator Steven DuBois, MD
15. A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma
    Principal Investigator Steven DuBois, MD
16. A Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX-101) in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors
    Principal Investigator Steven DuBois, MD
17. Phase I Study of Carfilzomib in Combination with Cyclophosphamide and Etoposide for Children with Relapsed and Refractory Solid Tumors and Leukemias
    Principal Investigator Steven DuBois, MD
18. A Phase I/II, Multicenter, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients with Previously Treated Solid Tumors
    Principal Investigator Steven DuBois, MD
19. A Phase 1 Study of Selinexor (KPT-330), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
    Principal Investigator Suzanne Shusterman, MD
20. Phase I Open Label, Dose Escalation, Monotherapy Trial of Afatinib to Determine the MTD, Safety, PK and Efficacy of Afatinib in Children Aged 2 Years to <18 Years with Recurrent/Refractory Neuroectodermal Tumours, Rhabdomyosarcoma and Tumours with ErbB Pathway Deregulation
    Principal Investigator Karen Wright, MD
21. An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor Trametinib in Children and Adolescents Subjects with Cancer or Plexiform Neurofibromas and Trametinib in Combination with Dabrafenib in Children and Adolescents with Cancers Harboring V600 Mutations
    Principal Investigator Karen Wright, MD
22. Phase I Study of Olaparib with Irinotecan and/or Temezolomide in Adolescent and Adult Patients with Recurrent/Metastatic Ewing’s Sarcoma Following Failure of Prior Chemotherapy
    Principal Investigator Steven DuBois, MD

Contact us
Not sure which clinical trials might be right for your child? Email our clinical trials team at clinicaltrials@danafarberbostonchildrens.org.

1. A Phase 1/2 Study of VX15/2503 (IND# 136181) in Children, Adolescents, or Young Adults with Recurrent or Relapsed Solid Tumors
   Principal Investigator: Steven DuBois, MD
2. Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer
   Principal Investigator: Steven DuBois, MD
3. A Safety and Pharmacokinetic Study of Single Agent REGN2810 in Pediatric Patients with Relapsed or Refractory Solid or Central Nervous System (CNS) Tumors and a Safety and Efficacy Trial of REGN2810 in Combination with Radiotherapy in Pediatric Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Newly Diagnosed High-Grade Glioma, or Recurrent High-Grade Glioma
   Principal Investigator: Susan Chi, MD
4. A Phase 1 Study of Pevonedistat (MLN4924, IND# 136078), A NEDD8 Activating Enzyme (NAE) Inhibitor, In Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors
   Principal Investigator Steven DuBois, MD
5. Phase 1 Trial of The LSD1 Inhibitor SP-2577 In Patients with Relapsed or Refractory Ewing Sarcoma
   Principal Investigator Steven DuBois, MD
6. A Phase 1 Study of ABI-009 (Nab-Rapamycin) (IND# 133537) In Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors As A Single Agent and in Combination with Temozolomide and Irinotecan
   Principal Investigator Steven DuBois, MD
7. Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
   Principal Investigator Suzanne Shusterman, MD
8. A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients with Relapsed or Refractory Malignancies
   Principal Investigator Andrew Place, MD
9. A Phase 1/2 Study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects with Previously Treated NTRK Fusion Cancers
   Principal Investigator Steven DuBois, MD
10. Phase 1 Study of Pazopanib in Combination with Irinotecan and Temozolomide (PAZIT) for Children and Young Adults with Relapsed or Refractory Sarcoma
    Principal Investigator Steven DuBois, MD
11. A Phase II Study of Pazopanib (GW786034, NSC# 737754 in Children, Adolescents and Young Adults with Refractory Solid Tumors
    Principal Investigator Suzanne Shusterman, MD
12. A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors
    Principal Investigator Steven DuBois, MD, MS
13. Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab
    Principal Investigator Steven DuBois, MD
14. A Phase 1/2 Study of AZD1775 (MK-1775) In Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors
    Principal Investigator Steven DuBois, MD
15. Phase 1 Trial of CUDC-907 in Children and Young Adults with Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
    Principal Investigator Steven DuBois, MD
16. A Phase I/II Study of Pembrolizumab (MK-3475) in Children with Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma
    Principal Investigator Steven DuBois, MD
17. A Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX-101) in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors
    Principal Investigator Steven DuBois, MD
18. A Phase 1 Study of Selinexor, a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
    Principal Investigator Suzanne Shusterman, MD
19. A Phase I/II, Multicenter, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients with Previously Treated Solid Tumors
    Principal Investigator Steven DuBois, MD
20. A Phase II Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapse or Refractory Synovial Sarcoma
    Principal Investigator Gregory Cote, MD
21. A Phase I Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects with Relapse or Refractory INI1-Negative Tumors or Synovial Sarcoma
    Principal Investigator Susan Chi, MD
22. An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor Trametinib in Children and Adolescents Subjects with Cancer or Plexiform Neurofibromas and Trametinib in Combination with Dabrafenib in Children and Adolescents with Cancers Harboring V600 Mutations
    Principal Investigator Karen Wright, MD
23. Phase I Study of Olaparib with Irinotecan and/or Temozolomide in Adolescent and Adult Patients with Recurrent/Metastatic Ewing's Sarcoma Following Failure of Prior Chemotherapy
    Principal Investigator Steven DuBois, MD

Contact us
Not sure which clinical trials might be right for your child? Email our clinical trials team at clinicaltrials@danafarberbostonchildrens.org.

1. A Phase I Trial of Autologous T-Lymphocytes (CAR T-Cell) Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients with Relapsed B-Cell Acute Lymphoblastic Leukemia
   Principal Investigator Lewis Silverman, MD

Contact us
Not sure which clinical trials might be right for your child? Email our clinical trials team at clinicaltrials@danafarberbostonchildrens.org.